Dr. Kulumani was born and raised in India, where she earned my MBBS degree at JIPMER Puducherry. Her love for cells and pathophysiology began when she worked at MD Anderson Cancer Center, studying the immune microenvironment in tumors and how radiation affects the immunogenicity of tumors. Dr. Kulumani also worked in translational neuro-oncology at Ohio State University, testing the biological effects of HSP90 inhibitor in mouse PDX models of glioma. This ignited her interest in glioma tumor biology. Dr. Kulumani is currently pursuing anatomic and clinical pathology residency training at Georgetown University, Washington DC. Her special interest lies in molecular mechanisms of tumorigenesis in glioblastoma, and she will be pursuing a clinical fellowship in Neuropathology after her AP/CP residency training at Mount Sinai Hospital NY.
Dr. Kulumani’s study titled GlioMark: a digital biomarker quantification tool for clinical diagnostics and therapeutic response prediction in gliomas aims to:
- Develop a panel of immunohistochemical stains, along with a digital quantification platform, for glioma diagnosis and classification. This will facilitate identifying patients eligible for targeted therapy and monitoring their treatment response.
- To advance personalized medicine for glioma patients by providing a robust, scalable platform for accurate biomarker quantification and therapeutic stratification.
ConduITS is supported by NCATS of the NIH’s CTSA Program. Any use of CTSA-supported resources requires citation of grant number UL1TR004419 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required.
